Cryptococcosis

Cryptococcosis is a systemic, opportunistic fungal infection caused by the encapsulated yeast-like fungi of the genus Cryptococcus, primarily Cryptococcus neoformans and Cryptococcus gattii. The disease predominantly affects the respiratory tract, with a strong tropism for the central nervous system (CNS), but can disseminate to virtually any organ system. In veterinary medicine, cryptococcosis is most commonly recognized in cats, where it often presents as chronic rhinosinusitis or a firm subcutaneous facial mass, and less frequently in dogs, where it may manifest as CNS signs, ocular disease, or pulmonary involvement. The infection is acquired by inhalation of basidiospores from the environment, particularly from soil contaminated with avian droppings (especially pigeon excreta for C. neoformans) or from certain trees (eucalyptus and others for C. gattii). The disease can be localized or disseminated, and its clinical course ranges from subclinical to rapidly fatal, depending on the host's immune status and the fungal strain. Cryptococcosis is considered a major opportunistic infection in immunocompromised individuals, including those with retroviral infections, but it can also occur in immunocompetent hosts, particularly with C. gattii. The disease is characterized by granulomatous inflammation, and the yeast's polysaccharide capsule is a key virulence factor that inhibits phagocytosis and modulates the host immune response.

The primary etiological agents are Cryptococcus neoformans and Cryptococcus gattii, both basidiomycetous yeasts. C. neoformans has two varieties: C. neoformans var. grubii (serotype A) and C. neoformans var. neoformans (serotype D), with serotype A being the most common worldwide. C. gattii (serotypes B and C) is now recognized as a distinct species and is more commonly associated with infections in immunocompetent hosts and in specific geographic regions (e.g., Pacific Northwest of North America, Australia, Papua New Guinea). The fungi exist in the environment as yeast cells or as basidiospores, which are the infectious particles. The major environmental reservoir for C. neoformans is avian droppings, particularly pigeon guano, where the fungus thrives due to the high nitrogen content and alkaline pH. C. gattii is associated with certain tree species, including eucalyptus, and has been found in soil and decaying wood. Transmission occurs primarily via inhalation of aerosolized basidiospores or desiccated yeast cells. There is no direct animal-to-animal or zoonotic transmission, although immunocompromised humans can be infected from the same environmental sources. Virulence factors include the polysaccharide capsule (primarily glucuronoxylomannan), which inhibits phagocytosis, suppresses T-cell responses, and promotes immune evasion; melanin production, which protects against oxidative stress; and the ability to grow at mammalian body temperature (37°C). The fungus can also form biofilms and undergo phenotypic switching, contributing to chronicity and resistance to therapy.

Cryptococcosis occurs worldwide, but the incidence varies geographically. In veterinary medicine, the disease is most commonly reported in cats, with a higher prevalence in certain regions such as Australia, the Pacific Northwest of the United States, and parts of Canada. Dogs are less frequently affected. There is no strong breed or sex predisposition, but young to middle-aged animals (2-7 years) are more commonly affected. In cats, the disease is often associated with immunosuppression, particularly feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections, although many cats are immunocompetent. In dogs, concurrent immunosuppressive conditions (e.g., lymphoma, hyperadrenocorticism, or immunosuppressive therapy) may predispose to infection. C. gattii infections are more likely to occur in immunocompetent animals and have been reported in outbreaks in the Pacific Northwest, affecting both humans and animals. The environmental distribution is influenced by climate, with C. neoformans being more prevalent in urban areas with high pigeon populations, while C. gattii is found in rural and coastal areas with specific tree species. Seasonality is not well-defined, but increased rainfall and humidity may promote fungal growth. The exact incidence in domestic animals is unknown, but it is considered an uncommon to rare disease. However, in endemic areas, it should be a differential for chronic respiratory or neurological signs.

The infection begins with inhalation of basidiospores or desiccated yeast cells into the alveoli. The spores are small enough to reach the lower respiratory tract. In the lung, the fungus encounters alveolar macrophages. The polysaccharide capsule is a major virulence factor that inhibits phagocytosis by preventing recognition by complement and mannose receptors. The yeast can survive and replicate within macrophages, using them as a vehicle for dissemination. The initial pulmonary infection may be subclinical or cause mild respiratory signs. From the lungs, the fungus can spread hematogenously or lymphatically to other organs, with a particular tropism for the central nervous system (CNS). The CNS invasion occurs by crossing the blood-brain barrier, either transcellularly, paracellularly, or via a 'Trojan horse' mechanism within infected macrophages. Once in the CNS, the yeast causes meningoencephalitis, leading to neurological signs. The immune response is primarily cell-mediated, with Th1-type cytokines (e.g., IFN-γ, TNF-α) being crucial for control. In immunocompromised hosts, the infection can disseminate widely. The tissue reaction is typically granulomatous, with accumulation of macrophages, lymphocytes, and plasma cells. The yeast cells are often seen as spherical, budding organisms surrounded by a clear capsule. Chronic infection can lead to fibrosis and tissue destruction. In cats, the upper respiratory tract is a common site, with the formation of granulomatous masses in the nasal cavity and sinuses. In dogs, CNS and ocular involvement are more common. The clinical signs reflect the organ systems affected, and the disease can be rapidly progressive if untreated.

Several factors increase the risk of cryptococcosis. Immunosuppression is a major predisposing factor, particularly in cats with concurrent FeLV or FIV infection. In dogs, conditions such as lymphoma, hyperadrenocorticism, or prolonged use of immunosuppressive drugs (e.g., corticosteroids, cyclosporine) can predispose to infection. Stress, malnutrition, and concurrent infections may also impair immune function. Environmental exposure is a key factor; animals living in areas with high pigeon populations or in endemic regions for C. gattii are at increased risk. Certain breeds may have a genetic predisposition, but this is not well-established. Age is a factor, with young to middle-aged animals being more commonly affected, possibly due to increased outdoor exposure. In cats, the disease is more common in males, possibly due to roaming behavior. Additionally, the virulence of the fungal strain plays a role; C. gattii is more pathogenic in immunocompetent hosts. There is no evidence of direct transmission from animals to humans, but immunocompromised owners should be aware of the environmental risk.

Clinical signs of cryptococcosis vary depending on the species and the organ systems involved. In cats, the most common presentation is chronic rhinosinusitis, with sneezing, nasal discharge (often mucopurulent or bloody), and the presence of a firm, fleshy polypoid mass in the nasal cavity or on the bridge of the nose. Subcutaneous nodules or ulcers on the face, especially over the bridge of the nose, are also common. In some cats, the infection may involve the CNS, leading to behavioral changes, seizures, ataxia, circling, and blindness. Ocular signs include uveitis, chorioretinitis, and retinal detachment. In dogs, the disease often presents with CNS signs such as seizures, ataxia, paresis, and altered mentation. Ocular involvement is also common, with uveitis, glaucoma, and retinal detachment. Respiratory signs may include cough, dyspnea, and abnormal lung sounds. Disseminated disease can affect the skin, bones, lymph nodes, and other organs. The onset can be insidious, with weight loss, lethargy, and anorexia. In some cases, the infection may be subclinical, detected incidentally. The clinical course can be acute or chronic, and without treatment, the disease is often fatal.

Differential diagnoses for cryptococcosis include other fungal infections such as blastomycosis, histoplasmosis, coccidioidomycosis, and aspergillosis. Bacterial rhinosinusitis, nasal foreign bodies, nasal tumors (e.g., adenocarcinoma, lymphoma), and chronic rhinitis due to other causes (e.g., feline herpesvirus, calicivirus) should also be considered. For CNS signs, other infectious causes (e.g., toxoplasmosis, neosporosis, canine distemper, feline infectious peritonitis), inflammatory diseases (e.g., granulomatous meningoencephalomyelitis), and neoplasia (e.g., lymphoma, meningioma) are differentials. Ocular signs may mimic other causes of uveitis or retinal disease, including trauma, hypertension, and other systemic infections. Key differentiating features: Cryptococcosis often presents with a characteristic nasal mass or facial swelling in cats, and cytology or histopathology reveals encapsulated yeast. Blastomycosis typically causes pulmonary and ocular signs with pyogranulomatous inflammation and broad-based budding yeast. Histoplasmosis is associated with gastrointestinal and pulmonary signs, and the yeast are small, intracellular, and non-encapsulated. Coccidioidomycosis is more common in arid regions and causes respiratory and bone lesions. Aspergillosis is more common in dogs and causes nasal discharge with fungal plaques, and imaging shows turbinate destruction. Bacterial rhinitis is usually responsive to antibiotics, and cytology shows bacteria. Nasal tumors are more common in older animals and imaging shows a destructive mass. Definitive diagnosis of cryptococcosis is made by cytology, histopathology, antigen testing, or culture.

The diagnostic approach to cryptococcosis should be systematic. 1. History and physical examination: Suspect cryptococcosis in cats with chronic nasal discharge and a facial mass, or in any animal with unexplained CNS or ocular signs. 2. Baseline laboratory tests: Complete blood count (CBC), serum biochemistry, and urinalysis may show non-specific changes such as mild anemia, leukocytosis, hyperglobulinemia, and elevated liver enzymes. 3. Serology: The cryptococcal antigen test (latex agglutination or ELISA) on serum or CSF is highly sensitive and specific. A positive result supports the diagnosis. 4. Cytology: Fine-needle aspirates of nasal masses, subcutaneous nodules, or lymph nodes, and CSF analysis may reveal the characteristic narrow-based budding yeast with a thick polysaccharide capsule. India ink stain can highlight the capsule. 5. Histopathology: Biopsy of affected tissues shows granulomatous inflammation with yeast organisms. Special stains such as mucicarmine or PAS can confirm the capsule. 6. Imaging: Thoracic radiographs may show interstitial or nodular pulmonary infiltrates. Computed tomography (CT) or magnetic resonance imaging (MRI) of the head is useful for evaluating nasal masses and CNS involvement. 7. Fungal culture: Definitive identification can be made by culture on Sabouraud dextrose agar, but it is not always necessary if antigen testing and cytology are positive. 8. PCR: Molecular techniques can identify the species and genotype. 9. Rule out immunosuppressive conditions: Test for FeLV/FIV in cats. 10. Assess for dissemination: If CNS signs are present, perform CSF analysis and imaging. The diagnostic algorithm should be tailored to the clinical presentation, but antigen testing is the most rapid and reliable method.

Hematology: Complete blood count may reveal mild non-regenerative anemia, leukocytosis with neutrophilia, and lymphopenia. Eosinophilia is uncommon. Serum biochemistry: Hyperglobulinemia (often due to polyclonal gammopathy) is a common finding. Liver enzyme activities (ALT, ALP) may be mildly elevated. In cases with renal involvement, azotemia may be present. Urinalysis: Usually unremarkable unless there is renal dissemination, which may show proteinuria or hematuria. Blood gas analysis: May show hypoxemia if pulmonary disease is severe. Specific biomarkers: Serum cryptococcal antigen (CrAg) titers are the most important diagnostic test. Titers ≥1:8 are considered positive, and higher titers (≥1:256) are associated with more severe disease and poorer prognosis. In CNS cases, CSF analysis typically shows a mononuclear pleocytosis, elevated protein, and normal to low glucose. Cryptococcal antigen can also be detected in CSF. Serology for FeLV/FIV should be performed in cats. PCR assays for Cryptococcus DNA are available but not routinely used. Other biomarkers such as C-reactive protein (CRP) may be elevated but are non-specific.

Radiography: Thoracic radiographs may show diffuse interstitial or nodular pulmonary infiltrates, sometimes with hilar lymphadenopathy. In nasal cryptococcosis, radiographs of the skull may show soft tissue swelling and increased opacity in the nasal cavity, but these findings are non-specific. Ultrasonography: Abdominal ultrasound may be useful if there is organomegaly or suspected dissemination, but findings are non-specific. Computed Tomography (CT): CT of the head is highly valuable for evaluating nasal masses, turbinate destruction, and extension into the frontal sinuses or brain. It can also detect pulmonary nodules. Magnetic Resonance Imaging (MRI): MRI is the modality of choice for CNS involvement, showing meningeal enhancement, mass lesions, or hydrocephalus. Endoscopy: Rhinoscopy allows direct visualization of nasal masses and collection of biopsy samples. Bronchoscopy may be performed if pulmonary lesions are present. Echocardiography: Not typically indicated unless there is cardiac involvement, which is rare.

Cytology: Fine-needle aspirates of nasal masses, subcutaneous nodules, or lymph nodes, and CSF analysis can reveal the characteristic yeast. Cryptococcus neoformans appears as spherical to oval, narrow-based budding yeast cells, 4-10 μm in diameter, surrounded by a thick, non-staining capsule. India ink stain can highlight the capsule against a dark background. Wright-Giemsa stain shows the yeast as basophilic organisms with a clear halo. In CSF, the yeast may be seen with a mild mononuclear pleocytosis. Histopathology: Biopsy specimens show granulomatous inflammation with macrophages, lymphocytes, and plasma cells. The yeast organisms are often numerous and may be extracellular or within macrophages. Special stains such as mucicarmine, periodic acid-Schiff (PAS), or Gomori methenamine silver (GMS) are used to demonstrate the capsule and the yeast cell wall. The capsule stains pink with mucicarmine. In chronic lesions, fibrosis and necrosis may be present. The presence of the encapsulated yeast is pathognomonic.

Treatment of cryptococcosis involves systemic antifungal therapy, and in some cases, surgical debulking of large masses. The primary drugs used are fluconazole, itraconazole, and amphotericin B. Fluconazole is the drug of choice for most cases due to its excellent CNS penetration, oral bioavailability, and safety profile. The recommended dosage for cats and dogs is 10-20 mg/kg PO q12h (or 25-50 mg/kg PO q24h). Itraconazole is an alternative, but it has poorer CNS penetration and requires monitoring of liver enzymes. The dosage is 5-10 mg/kg PO q12-24h. Amphotericin B is reserved for severe, refractory, or rapidly progressive cases, especially with CNS involvement. It is given IV at 0.25-0.5 mg/kg three times weekly, with careful monitoring of renal function. Lipid-complexed amphotericin B (e.g., Abelcet) is less nephrotoxic. Flucytosine (5-FC) is sometimes used in combination with amphotericin B for CNS disease, at a dosage of 50-75 mg/kg PO q6-8h, but it is not widely available. Treatment should be continued for at least 1-2 months after clinical resolution and negative antigen titers, which may take 6-12 months or longer. Supportive care includes fluid therapy, nutritional support, and management of seizures if present. Surgical excision of nasal masses may be considered for obstructive lesions, but it is not curative. In cats, concurrent FeLV/FIV infection should be managed appropriately. Regular monitoring of serum cryptococcal antigen titers is essential to assess response to therapy.

The prognosis for cryptococcosis is guarded to good, depending on the severity and extent of the disease. Cats with localized nasal disease and low antigen titers (<1:256) have a good prognosis, with a reported survival rate of 70-80% with treatment. Dogs with CNS involvement have a poorer prognosis, with a mortality rate of up to 50%. Negative prognostic factors include high antigen titers (≥1:1024), CNS involvement, ocular involvement, and concurrent immunosuppressive conditions. The response to treatment is monitored by serial antigen titers; a four-fold decrease in titer within 2-3 months is a favorable sign. Relapses can occur, especially if treatment is discontinued prematurely. Long-term therapy (6-12 months) is often necessary. In severe cases, the disease can be fatal despite aggressive treatment. Overall, with appropriate therapy, many animals can achieve clinical remission, but lifelong monitoring may be required.

Follow-up is critical to monitor response to therapy and detect relapse. Re-evaluation should be performed every 2-4 weeks initially, then every 1-3 months. At each visit, a thorough physical examination, including neurological and ophthalmic examinations, should be performed. Serum cryptococcal antigen titers should be measured every 1-3 months; a declining titer indicates a good response. Treatment should be continued until the titer is negative or very low (≤1:8) and clinical signs have resolved. Once treatment is discontinued, titers should be rechecked at 3, 6, and 12 months to ensure no relapse. In animals with CNS involvement, repeat CSF analysis may be indicated. Liver enzymes and renal parameters should be monitored if using itraconazole or amphotericin B, respectively. Imaging (CT/MRI) may be repeated if there is concern for residual masses. Owners should be educated about the signs of relapse, such as recurrence of nasal discharge, neurological signs, or ocular changes. Long-term prognosis is good if the disease is controlled, but some animals may require lifelong therapy.

Pearls: 1. Cryptococcal antigen testing is the most sensitive and specific diagnostic tool; a positive result is highly suggestive of infection. 2. In cats with chronic nasal discharge and a facial mass, always consider cryptococcosis and perform cytology or antigen testing. 3. Fluconazole is the preferred antifungal due to its excellent CNS penetration and safety profile. 4. Treatment should be continued for at least 1-2 months after clinical resolution and negative antigen titers. 5. In endemic areas, consider cryptococcosis in any dog with unexplained CNS signs. Pitfalls: 1. Do not rely solely on cytology; the yeast may be scarce in some lesions, leading to false negatives. 2. Avoid using corticosteroids in suspected fungal infections, as they can worsen the disease. 3. Do not discontinue antifungal therapy prematurely, as relapse is common. 4. Be cautious with amphotericin B due to nephrotoxicity; monitor renal function closely. 5. In cats, always test for FeLV/FIV, as immunosuppression affects prognosis and treatment. 6. Do not confuse Cryptococcus with other yeast on cytology; the capsule is a key distinguishing feature.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1. Fluconazole: Dogs and cats: 10-20 mg/kg PO q12h (or 25-50 mg/kg PO q24h). For CNS infections, higher doses (up to 20 mg/kg q12h) may be used. Duration: 6-12 months or longer. Adverse effects: gastrointestinal upset, hepatotoxicity (rare). 2. Itraconazole: Dogs and cats: 5-10 mg/kg PO q12-24h. Use with food for optimal absorption. Monitor liver enzymes. Adverse effects: hepatotoxicity, cutaneous vasculitis (in dogs). 3. Amphotericin B (deoxycholate): Dogs: 0.25-0.5 mg/kg IV three times weekly, up to a cumulative dose of 4-8 mg/kg. Cats: 0.25-0.5 mg/kg IV three times weekly, up to 4-6 mg/kg. Pre-hydrate with saline to reduce nephrotoxicity. Monitor BUN and creatinine. 4. Lipid-complexed amphotericin B (Abelcet): Dogs and cats: 1-3 mg/kg IV three times weekly, up to a cumulative dose of 12-24 mg/kg. Less nephrotoxic. 5. Flucytosine: Dogs and cats: 50-75 mg/kg PO q6-8h. Used in combination with amphotericin B for CNS disease. Monitor for bone marrow suppression. 6. Adjunctive therapy: In severe CNS cases, some experts recommend adding flucytosine to fluconazole or amphotericin B. 7. Supportive care: Fluid therapy, antiemetics, and appetite stimulants as needed. 8. For seizures, use anticonvulsants such as phenobarbital (2-5 mg/kg PO q12h) or levetiracetam (20 mg/kg PO q8h). 9. In cats with concurrent FeLV/FIV, manage accordingly. 10. Drug interactions: Fluconazole can increase levels of cyclosporine, phenytoin, and warfarin. Itraconazole can increase levels of digoxin and cyclosporine. Amphotericin B can potentiate nephrotoxicity of aminoglycosides.

The literature on cryptococcosis in veterinary medicine is limited to retrospective studies, case series, and expert consensus. A landmark study by Trivedi et al. (2011) evaluated 30 cats with cryptococcosis and found that fluconazole was effective in 80% of cases, with a median treatment duration of 9 months. Another study by O'Brien et al. (2004) reported that cats with nasal cryptococcosis had a good prognosis, with a 70% survival rate. In dogs, a retrospective study by Sykes et al. (2010) found that CNS involvement was associated with a poorer prognosis, with a mortality rate of 50%. The use of cryptococcal antigen titers to monitor therapy is well-established, with a four-fold decrease in titer being a favorable indicator (Lester et al., 2004). The ACVIM consensus statement on fungal infections (2021) recommends fluconazole as the first-line treatment for cryptococcosis, with amphotericin B reserved for severe cases. There are no randomized controlled trials, but the evidence supports the use of azole antifungals. The combination of amphotericin B and flucytosine is recommended for severe CNS disease based on human literature. Overall, the evidence is based on expert opinion and retrospective studies, and further research is needed to optimize treatment protocols.